Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Metastatic Castration-resistant Prostate Cancer|Metastatic Ovarian Carcinoma
Interventions: DRUG: Talazoparib|DRUG: Belinostat
Sponsor: University of Michigan Rogel Cancer Center
Collaborators: Pfizer|Acrotech Biopharma Inc.